文献速递脊柱关节炎其他结缔组织病

幼年银屑病关节炎患儿在CARRA登记中启动依那西普后不良事件的发生与疾病活动度变化

Occurrence of adverse events and change in disease activity after initiation of etanercept in paediatric patients with juvenile psoriatic arthritis in the CARRA Registry.
PubMed 文献 · RMD Open · 2023-01-01

基于CARRA登记中226例接受依那西普的幼年银屑病关节炎患儿,191例纳入安全性分析、43例纳入有效性分析;AESI与SAE发生率低,6个月随访时部分患儿达到ACR-Ped 90、cJADAS10≤1.1及临床非活动性疾病。

要点

  • 226例JPsA患儿使用依那西普,安全性分析191例,有效性分析43例。
  • AESI与SAE发生率低,共5例事件:葡萄膜炎3例、新发神经病变1例、恶性肿瘤1例。
  • 6个月随访时7/15(46.7%)达ACR-Ped 90,9/25(36.0%)cJADAS10≤1.1,14/27(51.9%)临床非活动性疾病。

核心结论

  • CARRA登记数据显示依那西普治疗JPsA患儿安全,AESI与SAE发生率低,且有效,即使在小样本中评估亦如此。

研究设计与样本

  • 基于CARRA登记的分析,纳入诊断为JPsA并使用依那西普的患儿226例,其中191例符合安全性分析标准、43例符合有效性分析标准。

主要发现

  • 共5例事件:葡萄膜炎3例、新发神经病变1例、恶性肿瘤1例。
  • 葡萄膜炎发生率为每100患者年0.55(95%CI:0.18,1.69)。
  • 神经病变发生率为每100患者年0.18(95%CI:0.03,1.29)。
  • 恶性肿瘤发生率为每100患者年0.13(95%CI:0.02,0.09)。
  • 6个月随访时7/15(46.7%)达ACR-Ped 90,9/25(36.0%)cJADAS10≤1.1,14/27(51.9%)达临床非活动性疾病。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出依那西普的有效性是在小样本中评估的。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Etanercept is commonly used to treat juvenile idiopathic arthritis, including juvenile psoriatic arthritis (JPsA); however, information on etanercept's safety and effectiveness in clinical practice is limited. We used data from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry to evaluate etanercept's safety and effectiveness in JPsA in clinical practice. METHODS: We analysed safety and effectiveness data for paediatric patients enrolled in the CARRA Registry who had a JPsA diagnosis and had used etanercept. Safety was assessed by calculating rates of prespecified adverse events of special interest (AESIs) and serious adverse events (SAEs). Effectiveness was assessed by a variety of disease activity measures. RESULTS: Overall, 226 patients had JPsA and received etanercept; 191 met criteria for safety analysis and 43 met criteria for effectiveness analysis. AESI and SAE incidence rates were low. There were five events: three uveitis, one new-onset neuropathy and one malignancy. Incidence rates were 0.55 (95% CI: 0.18, 1.69), 0.18 (95% CI: 0.03, 1.29) and 0.13 (95% CI: 0.02, 0.09) per 100 patient-years for uveitis, neuropathy and malignancy, respectively. Etanercept showed effectiveness for JPsA treatment; 7 of 15 (46.7%) had an American College of Rheumatology-Pediatric Response 90, 9 of 25 (36.0%) had a clinical Juvenile Arthritis Disease Activity Score 10-joint ≤1.1 and 14 of 27 (51.9%) had clinically inactive disease at the 6-month follow-up. CONCLUSION: Data in the CARRA Registry showed that etanercept treatment was safe in treating children with JPsA, with low AESIs and SAEs. Etanercept was also effective, even when assessed in a small sample size.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Correll CK, Stryker S, Collier D, et al. Occurrence of adverse events and change in disease activity after initiation of etanercept in paediatric patients with juvenile psoriatic arthritis in the CARRA Registry. RMD Open. 2023. PMID: 37230760. doi:10.1136/rmdopen-2022-002943

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。